Showing results (321-330 of 377) with videos related to
Sort By:
Pageof 38
Plos One|October 5, 2018
Health-related quality of life in patients with autoimmune hepatitis: A questionnaire surveyAtsushi Takahashi, Kei Moriya, Hiromasa Ohira, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 6, 2021
Evidence-based clinical practice guidelines for liver cirrhosis 2020Hitoshi Yoshiji, Sumiko Nagoshi, Takemi Akahane, et al.Journal of Gastroenterology|July 7, 2021
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020Hitoshi Yoshiji, Sumiko Nagoshi, Takemi Akahane, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 13, 2023
Hemoglobin levels as a surrogate marker of sarcopenia in patients with liver cirrhosisAkihiko Shibamoto, Tadashi Namisaki, Junya Suzuki, et al.Biomedical Reports|February 20, 2016
Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetesTsuyoshi Mashitani, Ryuichi Noguchi, Yasushi Okura, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Fibrosis stage is an independent predictor of liver-related complications in primary biliary cholangitisYukihisa Fujinaga, Tadashi Namisaki, Yuki Tsuji, et al.Journal of Gastroenterology|August 10, 2016
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infectionJoji Toyota, Yoshiyasu Karino, Fumitaka Suzuki, et al.Journal of Gastroenterology|December 1, 2018
A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 updateRyosuke Tateishi, Koji Uchino, Naoto Fujiwara, et al.International Journal of Molecular Sciences|May 14, 2025
Clinical Significance of Marginal Zinc Deficiency as a Predictor of Covert Hepatic Encephalopathy in Patients with Liver CirrhosisTakuya Matsuda, Tadashi Namisaki, Akihiko Shibamoto, et al.Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology|March 13, 2022
Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosisTadashi Namisaki, Kosuke Kaji, Naotaka Shimozato, et al.Pageof 38